Biophysical characterization of an indolinone inhibitor in the ATP-binding site of DNA gyrase

被引:14
作者
Oblak, Marko
Grdadolnik, Simona Golic
Kotnik, Miha
Poterszman, Arnaud
Atkinson, R. Andrew
Nierengarten, Helene
Desplancq, Dominique
Moras, Dino
Solmajer, Tom
机构
[1] Natl Inst Chem, Lab Mol Modeling & NMR Spectroscopy, SI-1001 Ljubljana, Slovenia
[2] Lek Pharmaceut, Drug Discovery, SI-1265 Ljubljana, Slovenia
[3] Univ Strasbourg 1, INSERM, CNRS,Dept Biol & Genom Struct, Inst Genet & Biol Mol & Cellulaire,UMR 7104, F-67404 Illkirch Graffenstaden, France
[4] Ecole Super Biotechnol Strasbourg, LCI, UMR 7175, Lab Biotechnol Interact Macromol, F-67412 Illkirch Graffenstaden, France
关键词
DNA gyrase; indolinone; ATP-binding site; biophysical methods; molecular modeling;
D O I
10.1016/j.bbrc.2006.08.172
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Fighting bacterial resistance is a challenging task in the field of medicinal chemistry. DNA gyrase represents a validated antibacterial target and has drawn much interest in recent years. By a structure-based approach we have previously discovered compound 1, an indolinone derivative, possessing inhibitory activity against DNA gyrase. In the present paper, a detailed biophysical characterization of this inhibitor is described. Using mass spectrometry, NMR spectroscopy, and fluorescence experiments we have demonstrated that compound I binds reversibly to the ATP-binding site of the 24 kDa N-terminal fragment of DNA gyrase B from Escherichia coli (GyrB24) with low micromolar affinity. Based on these data, a plausible molecular model of compound 1 in the active site of GyrB24 was constructed. The predicted binding mode explains the competitive inhibitory mechanism with respect to ATP and forms a useful basis for further development of potent DNA gyrase inhibitors. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:1206 / 1213
页数:8
相关论文
共 42 条
[1]   Ligand efficiency indices as guideposts for drug discovery [J].
Abad-Zapatero, C ;
Metz, JT .
DRUG DISCOVERY TODAY, 2005, 10 (07) :464-469
[2]   New antibacterial agents derived from the DNA gyrase inhibitor cyclothialidine [J].
Angehrn, P ;
Buchmann, S ;
Funk, C ;
Goetschi, E ;
Gmuender, H ;
Hebeisen, P ;
Kostrewa, D ;
Link, H ;
Luebbers, T ;
Masciadri, R ;
Nielsen, J ;
Reindl, P ;
Ricklin, F ;
Schmitt-Hoffmann, A ;
Theil, FP .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (06) :1487-1513
[3]   The Protein Data Bank [J].
Berman, HM ;
Westbrook, J ;
Feng, Z ;
Gilliland, G ;
Bhat, TN ;
Weissig, H ;
Shindyalov, IN ;
Bourne, PE .
NUCLEIC ACIDS RESEARCH, 2000, 28 (01) :235-242
[4]   Determination of the MurD mechanism through crystallographic analysis of enzyme complexes [J].
Bertrand, JA ;
Auger, G ;
Martin, L ;
Fanchon, E ;
Blanot, D ;
La Beller, D ;
van Heijenoort, J ;
Dideberg, O .
JOURNAL OF MOLECULAR BIOLOGY, 1999, 289 (03) :579-590
[5]   Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening [J].
Boehm, HJ ;
Boehringer, M ;
Bur, D ;
Gmuender, H ;
Huber, W ;
Klaus, W ;
Kostrewa, D ;
Kuehne, H ;
Luebbers, T ;
Meunier-Keller, N .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (14) :2664-2674
[6]  
Breeze A. L., 2005, [No title captured], Patent No. [WO 2005/026149, 2005026149, WO2005026149]
[7]   Dimerization of Escherichia coli DNA-gyrase B provides a structural mechanism for activating the ATPase catalytic center [J].
Brino, L ;
Urzhumtsev, A ;
Mousli, M ;
Bronner, C ;
Mitschler, A ;
Oudet, P ;
Moras, D .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (13) :9468-9475
[8]  
CHARIFSON P, 2001, Patent No. 0152845
[9]   The future challenges facing the development of new antimicrobial drugs [J].
Coates, A ;
Hu, YM ;
Bax, R ;
Page, C .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (11) :895-910
[10]   Protein kinases - the major drug targets of the twenty-first century? [J].
Cohen, P .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (04) :309-315